Apollo Hospitals Enterprise Ltd.

Apollo Hospitals Enterprise is currently trading at Rs. 940.25, up by 1.75 points or 0.19% from its previous closing of Rs. 938.50 on the BSE.

The scrip opened at Rs. 930.00 and has touched a high and low of Rs. 951.00 and Rs. 930.00 respectively. So far 2780 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1096.15 on 17-May-2013 and a 52 week low of Rs. 802.00 on 20-Aug-2013.

Last one week high and low of the scrip stood at Rs. 961.60 and Rs. 921.50 respectively. The current market cap of the company is Rs. 13209.93 crore.

The promoters holding in the company stood at 34.35%, while Institutions and Non-Institutions held 45.37% and 19.52% respectively.

Apollo Hospitals' subsidiary, Sapien Biosciences will introduce several genomic tests, over the next few months, as part of its personalized medicine initiative. Genomic testing involves analyses of the patient genomes and translating insights gained from these analyses to develop better healthcare interventions by the way of better prognostic tools for improved disease screening and prevention strategies, better diagnostic tests for optimization of clinical care and better theranostic tests for personalization of treatment.

The first of these tests is to be launched shortly; there shall be a clinical genomics panel for oncology that is designed to identify the mutations that drive cancer initiation and progression. Insights obtained from this test will enable prediction of the patient's response to their medication allowing the physician to tailor the treatment to the patient's genomic profile.

Apollo Hospitals is the leading private sector healthcare provider in Asia and owns and manages a network of speciality hospitals and clinics, a chain of Pharmacy retail outlets across the country, and provides Consultancy Services for commissioning and managing the Speciality Hospitals.